Logo image of ADTX

ADITXT INC (ADTX) Stock Fundamental Analysis

NASDAQ:ADTX - Nasdaq - US0070258027 - Common Stock - Currency: USD

2.24  -0.26 (-10.4%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ADTX. ADTX was compared to 568 industry peers in the Biotechnology industry. ADTX has a bad profitability rating. Also its financial health evaluation is rather negative. ADTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ADTX had negative earnings in the past year.
ADTX had a negative operating cash flow in the past year.
ADTX had negative earnings in each of the past 5 years.
ADTX had a negative operating cash flow in each of the past 5 years.
ADTX Yearly Net Income VS EBIT VS OCF VS FCFADTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

ADTX has a Return On Assets of -125.54%. This is amonst the worse of the industry: ADTX underperforms 80.99% of its industry peers.
With a Return On Equity value of -454.96%, ADTX is not doing good in the industry: 78.35% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -125.54%
ROE -454.96%
ROIC N/A
ROA(3y)-152.11%
ROA(5y)-160.9%
ROE(3y)-396.44%
ROE(5y)-345.59%
ROIC(3y)N/A
ROIC(5y)N/A
ADTX Yearly ROA, ROE, ROICADTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

ADTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADTX Yearly Profit, Operating, Gross MarginsADTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

ADTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADTX has more shares outstanding
Compared to 5 years ago, ADTX has more shares outstanding
Compared to 1 year ago, ADTX has an improved debt to assets ratio.
ADTX Yearly Shares OutstandingADTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
ADTX Yearly Total Debt VS Total AssetsADTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -10.90, we must say that ADTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.90, ADTX is not doing good in the industry: 76.58% of the companies in the same industry are doing better.
ADTX has a Debt/Equity ratio of 0.64. This is a neutral value indicating ADTX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.64, ADTX is not doing good in the industry: 75.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -10.9
ROIC/WACCN/A
WACC10.35%
ADTX Yearly LT Debt VS Equity VS FCFADTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

ADTX has a Current Ratio of 0.09. This is a bad value and indicates that ADTX is not financially healthy enough and could expect problems in meeting its short term obligations.
ADTX has a Current ratio of 0.09. This is amonst the worse of the industry: ADTX underperforms 97.54% of its industry peers.
A Quick Ratio of 0.08 indicates that ADTX may have some problems paying its short term obligations.
ADTX's Quick ratio of 0.08 is on the low side compared to the rest of the industry. ADTX is outperformed by 97.54% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.08
ADTX Yearly Current Assets VS Current LiabilitesADTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

ADTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -9344.74%.
The Revenue for ADTX has decreased by -79.24% in the past year. This is quite bad
ADTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.
EPS 1Y (TTM)-9344.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.32%
Revenue 1Y (TTM)-79.24%
Revenue growth 3Y6.8%
Revenue growth 5YN/A
Sales Q2Q%-96.1%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2096.63%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1584.79%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADTX Yearly Revenue VS EstimatesADTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 5M 10M 15M 20M
ADTX Yearly EPS VS EstimatesADTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -5M -10M -15M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADTX. In the last year negative earnings were reported.
Also next year ADTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADTX Price Earnings VS Forward Price EarningsADTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADTX Per share dataADTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20K -40K -60K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ADTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADITXT INC

NASDAQ:ADTX (4/21/2025, 2:28:30 PM)

2.24

-0.26 (-10.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-14 2025-04-14/bmo
Earnings (Next)05-19 2025-05-19
Inst Owners0.1%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap2.60M
Analysts80
Price TargetN/A
Short Float %12.42%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.73%
Min Revenue beat(2)-99.26%
Max Revenue beat(2)-98.2%
Revenue beat(4)0
Avg Revenue beat(4)-90.25%
Min Revenue beat(4)-99.26%
Max Revenue beat(4)-75.96%
Revenue beat(8)0
Avg Revenue beat(8)-66.24%
Revenue beat(12)0
Avg Revenue beat(12)-65.19%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.38
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-70338.18
EYN/A
EPS(NY)-252.96
Fwd EYN/A
FCF(TTM)-14.45
FCFYN/A
OCF(TTM)-14.45
OCFYN/A
SpS0.12
BVpS7.65
TBVpS7.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.54%
ROE -454.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-152.11%
ROA(5y)-160.9%
ROE(3y)-396.44%
ROE(5y)-345.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.08
Altman-Z -10.9
F-Score2
WACC10.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9344.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.32%
EPS Next Y-2096.63%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-79.24%
Revenue growth 3Y6.8%
Revenue growth 5YN/A
Sales Q2Q%-96.1%
Revenue Next Year1584.79%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.71%
OCF growth 3YN/A
OCF growth 5YN/A